{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:45:55Z","timestamp":1782535555488,"version":"3.54.5"},"reference-count":40,"publisher":"Medical Association of Nippon Medical School","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2026,6,20]]},"DOI":"10.1272\/jnms.jnms.2026_93-308","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T22:08:43Z","timestamp":1782425323000},"page":"236-243","source":"Crossref","is-referenced-by-count":0,"title":["Tau Accumulation and Dopamine Transporter Availability in Elderly Adults with Depression"],"prefix":"10.1272","volume":"93","author":[{"given":"Shotaro","family":"Uchiyama","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sakayori","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Nogami","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Ohya","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amane","family":"Tateno","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965 Nov;122 (5):509\u201322.","DOI":"10.1176\/ajp.122.5.509"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Belujon P, Grace AA. Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol. 2017 Dec 1;20 (12):1036\u201346.","DOI":"10.1093\/ijnp\/pyx056"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Camardese G, Di Giuda D, Di Nicola M, et al. Imaging studies on dopamine transporter and depression: a review of literature and suggestions for future research. J Psychiatr Res. 2014 Apr;51:7\u201318.","DOI":"10.1016\/j.jpsychires.2013.12.006"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Moriya H, Tiger M, Tateno A, et al. Low dopamine transporter binding in the nucleus accumbens in geriatric patients with severe depression. Psychiatry Clin Neurosci. 2020 Aug;74 (8):424\u201330.","DOI":"10.1111\/pcn.13020"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Adams KB. Depressive symptoms, depletion, or developmental change? Withdrawal, apathy, and lack of vigor in the Geriatric Depression Scale. Gerontologist. 2001 Dec;41 (6):768\u201377.","DOI":"10.1093\/geront\/41.6.768"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci. 2013 Sep;14 (9):609\u201325.","DOI":"10.1038\/nrn3381"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Misaki M, Suzuki H, Savitz J, Drevets WC, Bodurka J. Individual variations in nucleus accumbens responses associated with major depressive disorder symptoms. Sci Rep. 2016 Feb 16;6:21227.","DOI":"10.1038\/srep21227"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005 Nov;34 (6):561\u20136.","DOI":"10.1093\/ageing\/afi190"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Elbaz A, Carcaillon L, Kab S, Moisan F. Epidemiology of Parkinson&apos;s disease. Rev Neurol (Paris). 2016 Jan;172 (1):14\u201326.","DOI":"10.1016\/j.neurol.2015.09.012"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Walker Z, Costa DC, Walker RW, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology. 2004 May 11;62 (9):1568\u201372.","DOI":"10.1212\/01.WNL.0000123248.39847.1D"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Elbaz A. Prodromal symptoms of Parkinson&apos;s disease: implications for epidemiological studies of disease etiology. Rev Neurol (Paris). 2016 Aug-Sep;172 (8-9):503\u201311.","DOI":"10.1016\/j.neurol.2016.07.001"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017 Jul;18 (7):435\u201350.","DOI":"10.1038\/nrn.2017.62"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Takahashi S, Mizukami K, Arai T, et al. Ventilatory response to hypercapnia predicts dementia with Lewy bodies in late-onset major depressive disorder. J Alzheimers Dis. 2016;50 (3):751\u20138.","DOI":"10.3233\/JAD-150507"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol. 2011 May 3;7 (6):323\u201331.","DOI":"10.1038\/nrneurol.2011.60"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry. 2011 Feb;72 (2):126\u201333.","DOI":"10.4088\/JCP.10m06382oli"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tateno A, Nogami T, Sakayori T, Yamamoto K, Okubo Y. Depression as a prodromal symptom of neurodegenerative diseases. J Nippon Med Sch. 2023;90 (2):157\u201364.","DOI":"10.1272\/jnms.JNMS.2023_90-216"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Moriguchi S, Takahata K, Shimada H, et al. Excess tau PET ligand retention in elderly patients with major depressive disorder. Mol Psychiatry. 2021 Oct;26 (10):5856\u201363.","DOI":"10.1038\/s41380-020-0766-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kurose S, Moriguchi S, Kubota M, et al. Diverse tau pathologies in late-life mood disorders revealed by PET and autopsy assays. Alzheimers Dement. 2025 Jun;21 (6):e70195.","DOI":"10.1002\/alz.70195"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ferschmann C, Messerschmidt K, Gnorich J, et al. Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies. Eur J Nucl Med Mol Imaging. 2024 Jun;51 (7):1909\u201322.","DOI":"10.1007\/s00259-024-06637-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Schou M, Steiger C, Varrone A, Guilloteau D, Halldin C. Synthesis, radiolabeling, and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter. Bioorg Med Chem Lett. 2009 Aug 15;19 (16):4843\u20135.","DOI":"10.1016\/j.bmcl.2009.06.032"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Varrone A, Steiger C, Schou M, et al. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse. 2009 Oct;63 (10):871\u201380.","DOI":"10.1002\/syn.20670"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kim W, Tateno A, Arakawa R, et al. In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [<sup>18<\/sup>F]FE-PE2I. Int J Neuropsychopharmacol. 2014 May;17 (5):697\u2013703.","DOI":"10.1017\/S1461145713001612"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Shingai Y, Tateno A, Arakawa R, et al. Age-related decline in dopamine transporter in human brain using PET with a new radioligand [<sup>18<\/sup>F]FE-PE2I. Ann Nucl Med. 2014 Apr;28 (3):220\u20136.","DOI":"10.1007\/s12149-013-0798-1"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sasaki T, Ito H, Kimura Y, et al. Quantification of dopamine transporter in human brain using PET with [18F]FE-PE2I. J Nucl Med. 2012 Jul;53 (7):1065\u201373.","DOI":"10.2967\/jnumed.111.101626"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Jakobson Mo S, Axelsson J, Jonasson L, et al. Dopamine transporter imaging with [<sup>18<\/sup>F]FE-PE2I PET and [<sup>123<\/sup>I]FP-CIT SPECT: a clinical comparison. EJNMMI Res. 2018 Nov 15;8 (1):100.","DOI":"10.1186\/s13550-018-0450-0"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Tagai K, Ono M, Kubota M, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer&apos;s and non-Alzheimer&apos;s disease tauopathies. Neuron. 2021 Jan 6;109 (1):42\u201358.e8.","DOI":"10.1016\/j.neuron.2020.09.042"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Endo H, Tagai K, Ono M, et al. A machine learning-based approach to discrimination of tauopathies using [<sup>18<\/sup>F]PM-PBB3 PET images. Mov Disord. 2022 Nov;37 (11):2236\u201346.","DOI":"10.1002\/mds.29173"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kawamura K, Hashimoto H, Furutsuka K, et al. Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [<sup>18<\/sup>F]PM-PBB3 for clinical applications. J Labelled Comp Radiopharm. 2021 Mar;64 (3):109\u201319.","DOI":"10.1002\/jlcr.3890"},{"key":"29","unstructured":"29. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988."},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Pizzagalli DA, Berretta S, Wooten D, et al. Assessment of striatal dopamine transporter binding in individuals with major depressive disorder: in vivo positron emission tomography and postmortem evidence. JAMA Psychiatry. 2019 Aug 1;76 (8):854\u201361.","DOI":"10.1001\/jamapsychiatry.2019.0801"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003 Feb;28 (2):413\u201320.","DOI":"10.1038\/sj.npp.1300036"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Shang Y, Gibbs MA, Marek GJ, et al. Displacement of serotonin and dopamine transporters by venlafaxine extended-release capsule at steady state: a [123I]2\u03b2-carbomethoxy-3\u03b2-(4-iodophenyl) tropane single photon emission computed tomography imaging study. J Clin Psychopharmacol. 2007 Feb;27 (1):71\u20135.","DOI":"10.1097\/JCP.0b013e31802e0017"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Cilia R, Marotta G, Belletti A, Siri C, Pezzoli G. Reversible dopamine transporter reduction in drug-induced parkinsonism. Mov Disord. 2014 Apr;29 (4):575\u20137.","DOI":"10.1002\/mds.25828"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Hermida AP, Janjua AU, Glass OM, et al. A case of lithium-induced parkinsonism presenting with typical motor symptoms of Parkinson&apos;s disease in a bipolar patient. Int Psychogeriatr. 2016 Dec;28 (12):2101\u20134.","DOI":"10.1017\/S1041610216001101"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Pirker W, Asenbaum S, Kasper S, et al. \u03b2-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect. 1995;100 (3):247\u201356.","DOI":"10.1007\/BF01276462"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Mateos JJ, Lomena F, Parellada E, et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but suggests an illness trait. Psychopharmacology (Berl). 2007 Apr;191 (3):805\u201311.","DOI":"10.1007\/s00213-006-0570-5"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Chang WH, Chen KC, Lee IH, et al. Unaltered dopamine transporter availability in drug-naive patients with schizophrenia after 6 months of antipsychotic treatment: a naturalistic study. J Clin Psychopharmacol. 2017 Feb;37 (1):21\u20136.","DOI":"10.1097\/JCP.0000000000000632"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Sheline YI, West T, Yarasheski K, et al. Reply to comment on &quot;An antidepressant decreases CSF A\u03b2 production in healthy individuals and in transgenic AD mice&quot;. Sci Transl Med. 2014 Dec 24;6 (268):268lr4.","DOI":"10.1126\/scitranslmed.3010609"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Nelson RL, Guo Z, Halagappa VM, et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol. 2007 May;205 (1):166\u201376.","DOI":"10.1016\/j.expneurol.2007.01.037"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Zaki MO, Elsherbiny DA, Salama M, Azab SS. Potential role of drug repositioning strategy (DRS) for management of tauopathy. Life Sci. 2022 Feb 15;291:120267.","DOI":"10.1016\/j.lfs.2021.120267"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/93\/3\/93_JNMS.2026_93-308\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:04:49Z","timestamp":1782533089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/93\/3\/93_JNMS.2026_93-308\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2026_93-308","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"article-number":"JNMS.2026_93-308"}}